Get the Stockscreener App
2.08
1.89%
-0.04
After Hours:
2.06
-0.02
-0.96%
Oramed Pharmaceuticals Inc stock is traded at $2.08, with a volume of 132.55K.
It is down -1.89% in the last 24 hours and down -0.48% over the past month.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
See More
Previous Close:
$2.12
Open:
$2
24h Volume:
132.55K
Relative Volume:
1.87
Market Cap:
$84.96M
Revenue:
$2.70M
Net Income/Loss:
$5.53M
P/E Ratio:
18.91
EPS:
0.11
Net Cash Flow:
$-10.55M
1W Performance:
-0.48%
1M Performance:
-0.48%
6M Performance:
-13.33%
1Y Performance:
-11.49%
1-Day Range:
$1.975
$2.1242
1-Week Range:
$1.975
$2.143
52-Week Range:
$1.82
$3.09
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Name
Oramed Pharmaceuticals Inc
Sector
Industry
Phone
646-844-1164
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Compare ORMP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.08 | 86.59M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-18-22 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-20-21 | Initiated | Canaccord Genuity | Buy |
| Feb-09-21 | Initiated | National Securities | Buy |
| Dec-03-20 | Initiated | Alliance Global Partners | Buy |
| Mar-11-20 | Initiated | Aegis Capital | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-17 | Resumed | B. Riley FBR, Inc. | Buy |
| May-26-16 | Reiterated | FBR Capital | Outperform |
| Dec-01-15 | Reiterated | H.C. Wainwright | Buy |
| Nov-19-15 | Initiated | FBR Capital | Outperform |
| Apr-13-15 | Resumed | MLV & Co | Buy |
| Jan-30-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Reiterated | Aegis Capital | Buy |
| Jan-08-14 | Initiated | MLV & Co | Buy |
| Dec-03-13 | Initiated | Aegis Capital | Buy |
View All
Oramed Pharmaceuticals Inc Stock (ORMP) Latest News
Can machine learning forecast Oramed Pharmaceuticals Inc. recoveryTrend Reversal & Safe Entry Momentum Tips - Newser
How high can Oramed Pharmaceuticals Inc. stock price go in 2025Market Activity Recap & Real-Time Volume Analysis - Newser
Oramed Posts Earnings Beat Amid Mixed Pharmaceutical Sector Response; Momentum Favors Long-Term Holders - AInvest
Applying big data sentiment scoring on Oramed Pharmaceuticals Inc.2025 Earnings Impact & High Accuracy Investment Signals - Newser
Is Oramed Pharmaceuticals Inc. the Top Chart Pick This WeekMarket Volume Summary & Intraday High Probability Alerts - sundaytimes.kr
Backtesting results for Oramed Pharmaceuticals Inc. trading strategiesJuly 2025 Analyst Calls & Accurate Intraday Trade Tips - Newser
Oramed Pharmaceuticals Inc. Sees Spike in Bullish Option FlowWeekly Stock Report & Verified Momentum Stock Ideas - newsyoung.net
Can Oramed Pharmaceuticals Inc. lead its sector in growthMarket Activity Report & Weekly Breakout Watchlists - sundaytimes.kr
Recovery Signals Appearing in Oramed Pharmaceuticals Inc. ChartsWeekly Gains Report & Fast Entry High Yield Tips - sundaytimes.kr
Can volume confirm reversal in Oramed Pharmaceuticals Inc.Weekly Investment Summary & Accurate Buy Signal Alerts - Newser
Risk vs reward if holding onto Oramed Pharmaceuticals Inc.Quarterly Profit Report & Expert Approved Momentum Ideas - Newser
Can a trend reversal in Oramed Pharmaceuticals Inc. lead to recovery2025 Volatility Report & Safe Capital Preservation Plans - Newser
Is now a turning point for Oramed Pharmaceuticals Inc.July 2025 Recap & Low Risk Growth Stock Ideas - Newser
Detecting price anomalies in Oramed Pharmaceuticals Inc. with AIJuly 2025 Pullbacks & Entry Point Strategy Guides - Newser
Oramed: Q2 Earnings Snapshot - Norwalk Hour
What candlestick patterns are forming on Oramed Pharmaceuticals Inc.July 2025 Closing Moves & High Return Stock Watch Alerts - Newser
Oramed Pharmaceuticals: Navigating Earnings Volatility and Strategic Alliances in a High-Stakes Biotech Landscape - AInvest
Oramed Pharmaceuticals Inc. Stock Support and Resistance Levels You Should KnowQuarterly Profit Report & Fast Entry Momentum Trade Alerts - Newser
Oramed Pharmaceuticals shares rise 1.82% premarket after reporting Q1 revenue of $2 million. - AInvest
Scilex Holding Company Announces S-4 Effectiveness, Denali-Semnur Merger Proposal, and Oramed Pharmaceuticals Enters Option Agreement with Scilex - AInvest
Is Oramed Pharmaceuticals Inc. forming a reversal patternJuly 2025 Levels & Verified Swing Trading Watchlist - Newser
How to use Fibonacci retracement on Oramed Pharmaceuticals Inc.2025 Market Outlook & Smart Swing Trading Alerts - Newser
How high can Oramed Pharmaceuticals Inc. stock goFree Watchlist for Low Risk High Return - Newser
How Oramed Pharmaceuticals Inc. stock performs during market volatilityFree Daily Chart Pattern Stock Forecast - Newser
Alpha Tau Secures FDA Approval for Breakthrough Brain Cancer Treatment Trial, Raises $36.9M - Stock Titan
What to expect from Oramed Pharmaceuticals Inc. in the next 30 daysFree Stock Market Entry Timing Signals - Newser
Can you recover from losses in Oramed Pharmaceuticals Inc.Free Short Term High Yield Stock Tips - Newser
Published on: 2025-08-10 20:12:47 - Newser
Intraday pattern recognizer results for Oramed Pharmaceuticals Inc.Daily Exit and Entry Price Prediction - Newser
Oramed Pharmaceuticals Inc expected to post a loss of 19 cents a shareEarnings Preview - TradingView
Diabetic Ketacidosis Treatment Market Set to Witness - openPR.com
What makes Oramed Pharmaceuticals Inc. stock price move sharplyMulti-Year Investment Performance Summary Report - Newser
Published on: 2025-08-05 21:05:42 - Newser
Oramed Pharmaceuticals Inc Stock (ORMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):